XML 45 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Revenues
 6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
Xyrem$334,182 $446,808 $669,732 $854,683 
Xywav124,164 — 199,580 — 
   Total Oxybate458,346 446,808 869,312 854,683 
Epidiolex/Epidyolex109,481 — 109,481 — 
Sunosi12,124 8,578 23,730 10,502 
Sativex1,961 — 1,961 — 
Total Neuroscience581,912 455,386 1,004,484 865,185 
Zepzelca55,924 — 110,258 — 
Vyxeos31,453 26,568 64,608 59,288 
Defitelio/defibrotide 48,096 42,714 97,715 90,146 
Erwinaze/Erwinase28,314 32,683 69,382 70,415 
Total Oncology163,787 101,965 341,963 219,849 
Other2,641 852 5,424 3,374 
Product sales, net748,340 558,203 1,351,871 1,088,408 
Royalties and contract revenues3,471 4,233 7,521 8,754 
Total revenues$751,811 $562,436 $1,359,392 $1,097,162 
The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
United States$690,900 $515,402 $1,239,192 $993,191 
Europe47,270 37,599 94,503 78,508 
All other13,641 9,434 25,697 25,462 
Total revenues$751,811 $562,436 $1,359,392 $1,097,162 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
ESSDS63 %79 %65 %78 %
McKesson13 %10 %13 %11 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45 days.
Contract Liabilities - Deferred Revenue
The deferred revenue balance as of June 30, 2021 primarily related to deferred upfront fees received from Nippon Shinyaku Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements granting Nippon Shinyaku exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $0.8 million and $1.4 million during the three and six months ended June 30, 2021, respectively, relating to these upfront payments. The deferred revenue balances are being recognized over an average of four years representing the period over which we expect to perform our research and developments obligations under each agreement.
The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers for the six months ended June 30, 2021 (in thousands): 
Contract Liabilities
Balance as of December 31, 2020$4,861 
Additions484 
Amount recognized within royalties and contract revenues(1,394)
Balance as of June 30, 2021$3,951